Asia-Pacific NSCLC market to reach $2.9 billion by 2019

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion by 2019, at a compound annual growth rate (CAGR) of 6.3%.

According to business intelligence provider GBI Research’s latest report, Japan and China had the largest shares of the region’s NSCLC market in 2012, with 48.5% and 41.5%, respectively. Meanwhile, Australia and India had lower shares of 5.9% and 4.1%.

Sravanthi Addapally, senior analyst for GBI Research, says that an aging population and increasing number of NSCLC incident cases, especially in China and India, will be the main drivers behind the anticipated market growth. “Additionally, the expected launches of premium-priced novel antibodies and immunotherapies in the first and second lines of therapies, targeting both squamous and non-squamous NSCLC patients, will widen the eligible treatment population. This will ultimately maximize the patient share and provide a boost for the market,” Ms Addapally says.